Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
Stopped PI indicated departure from institution, inability to complete study.
Conditions
- Hereditary Angioedema Types I and II
Interventions
- DRUG: Ecallantide subcutaneous dosing
Sponsor
NYU Langone Health
Collaborators